featured
Activity and Safety of the Anti–PD-1 Antibody Dostarlimab for Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial
JAMA Oncol 2020 Oct 01;[EPub Ahead of Print], A Oaknin, AV Tinker, L Gilbert, V Samouëlian, C Mathews, J Brown, MP Barretina-Ginesta, V Moreno, A Gravina, C Abdeddaim, S Banerjee, W Guo, H Danaee, E Im, R SabatierFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.